1022 related articles for article (PubMed ID: 27030262)
1. B Cell Responses during Secondary Dengue Virus Infection Are Dominated by Highly Cross-Reactive, Memory-Derived Plasmablasts.
Priyamvada L; Cho A; Onlamoon N; Zheng NY; Huang M; Kovalenkov Y; Chokephaibulkit K; Angkasekwinai N; Pattanapanyasat K; Ahmed R; Wilson PC; Wrammert J
J Virol; 2016 Jun; 90(12):5574-85. PubMed ID: 27030262
[TBL] [Abstract][Full Text] [Related]
2. Pre-Existing Dengue Immunity Drives a DENV-Biased Plasmablast Response in ZIKV-Infected Patient.
Bhaumik SK; Priyamvada L; Kauffman RC; Lai L; Natrajan MS; Cho A; Rouphael N; Suthar MS; Mulligan MJ; Wrammert J
Viruses; 2018 Dec; 11(1):. PubMed ID: 30597938
[TBL] [Abstract][Full Text] [Related]
3. Isolation of dengue virus-specific memory B cells with live virus antigen from human subjects following natural infection reveals the presence of diverse novel functional groups of antibody clones.
Smith SA; de Alwis AR; Kose N; Jadi RS; de Silva AM; Crowe JE
J Virol; 2014 Nov; 88(21):12233-41. PubMed ID: 25100837
[TBL] [Abstract][Full Text] [Related]
4. The human immune response to Dengue virus is dominated by highly cross-reactive antibodies endowed with neutralizing and enhancing activity.
Beltramello M; Williams KL; Simmons CP; Macagno A; Simonelli L; Quyen NT; Sukupolvi-Petty S; Navarro-Sanchez E; Young PR; de Silva AM; Rey FA; Varani L; Whitehead SS; Diamond MS; Harris E; Lanzavecchia A; Sallusto F
Cell Host Microbe; 2010 Sep; 8(3):271-83. PubMed ID: 20833378
[TBL] [Abstract][Full Text] [Related]
5. Potent Neutralizing Human Monoclonal Antibodies Preferentially Target Mature Dengue Virus Particles: Implication for Novel Strategy for Dengue Vaccine.
Tsai WY; Chen HL; Tsai JJ; Dejnirattisai W; Jumnainsong A; Mongkolsapaya J; Screaton G; Crowe JE; Wang WK
J Virol; 2018 Dec; 92(23):. PubMed ID: 30185598
[TBL] [Abstract][Full Text] [Related]
6. Dengue virus antibody database: Systematically linking serotype-specificity with epitope mapping in dengue virus.
Chaudhury S; Gromowski GD; Ripoll DR; Khavrutskii IV; Desai V; Wallqvist A
PLoS Negl Trop Dis; 2017 Feb; 11(2):e0005395. PubMed ID: 28222130
[TBL] [Abstract][Full Text] [Related]
7. Potent Plasmablast-Derived Antibodies Elicited by the National Institutes of Health Dengue Vaccine.
Magnani DM; Silveira CGT; Ricciardi MJ; Gonzalez-Nieto L; Pedreño-Lopez N; Bailey VK; Gutman MJ; Maxwell HS; Domingues A; Costa PR; Ferrari L; Goulart R; Martins MA; Martinez-Navio JM; Fuchs SP; Kalil J; Timenetsky MDC; Wrammert J; Whitehead SS; Burton DR; Desrosiers RC; Kallas EG; Watkins DI
J Virol; 2017 Nov; 91(22):. PubMed ID: 28878078
[TBL] [Abstract][Full Text] [Related]
8. Generation of Monoclonal Antibodies against Dengue Virus Type 4 and Identification of Enhancing Epitopes on Envelope Protein.
Tang CT; Liao MY; Chiu CY; Shen WF; Chiu CY; Cheng PC; Chang GJ; Wu HC
PLoS One; 2015; 10(8):e0136328. PubMed ID: 26309127
[TBL] [Abstract][Full Text] [Related]
9. The potent and broadly neutralizing human dengue virus-specific monoclonal antibody 1C19 reveals a unique cross-reactive epitope on the bc loop of domain II of the envelope protein.
Smith SA; de Alwis AR; Kose N; Harris E; Ibarra KD; Kahle KM; Pfaff JM; Xiang X; Doranz BJ; de Silva AM; Austin SK; Sukupolvi-Petty S; Diamond MS; Crowe JE
mBio; 2013 Nov; 4(6):e00873-13. PubMed ID: 24255124
[TBL] [Abstract][Full Text] [Related]
10. Complexity of Neutralizing Antibodies against Multiple Dengue Virus Serotypes after Heterotypic Immunization and Secondary Infection Revealed by In-Depth Analysis of Cross-Reactive Antibodies.
Tsai WY; Durbin A; Tsai JJ; Hsieh SC; Whitehead S; Wang WK
J Virol; 2015 Jul; 89(14):7348-62. PubMed ID: 25972550
[TBL] [Abstract][Full Text] [Related]
11. Mapping the Human Memory B Cell and Serum Neutralizing Antibody Responses to Dengue Virus Serotype 4 Infection and Vaccination.
Nivarthi UK; Kose N; Sapparapu G; Widman D; Gallichotte E; Pfaff JM; Doranz BJ; Weiskopf D; Sette A; Durbin AP; Whitehead SS; Baric R; Crowe JE; de Silva AM
J Virol; 2017 Mar; 91(5):. PubMed ID: 28031369
[TBL] [Abstract][Full Text] [Related]
12. High-avidity and potently neutralizing cross-reactive human monoclonal antibodies derived from secondary dengue virus infection.
Tsai WY; Lai CY; Wu YC; Lin HE; Edwards C; Jumnainsong A; Kliks S; Halstead S; Mongkolsapaya J; Screaton GR; Wang WK
J Virol; 2013 Dec; 87(23):12562-75. PubMed ID: 24027331
[TBL] [Abstract][Full Text] [Related]
13. Engineered Dengue Virus Domain III Proteins Elicit Cross-Neutralizing Antibody Responses in Mice.
Frei JC; Wirchnianski AS; Govero J; Vergnolle O; Dowd KA; Pierson TC; Kielian M; Girvin ME; Diamond MS; Lai JR
J Virol; 2018 Sep; 92(18):. PubMed ID: 29976679
[TBL] [Abstract][Full Text] [Related]
14. Plasmablasts generated during repeated dengue infection are virus glycoprotein-specific and bind to multiple virus serotypes.
Xu M; Hadinoto V; Appanna R; Joensson K; Toh YX; Balakrishnan T; Ong SH; Warter L; Leo YS; Wang CI; Fink K
J Immunol; 2012 Dec; 189(12):5877-85. PubMed ID: 23152560
[TBL] [Abstract][Full Text] [Related]
15. Single-Cell Analysis of B Cell/Antibody Cross-Reactivity Using a Novel Multicolor FluoroSpot Assay.
Hadjilaou A; Green AM; Coloma J; Harris E
J Immunol; 2015 Oct; 195(7):3490-6. PubMed ID: 26320246
[TBL] [Abstract][Full Text] [Related]
16. A Dengue Virus Serotype 1 mRNA-LNP Vaccine Elicits Protective Immune Responses.
Wollner CJ; Richner M; Hassert MA; Pinto AK; Brien JD; Richner JM
J Virol; 2021 May; 95(12):. PubMed ID: 33762420
[TBL] [Abstract][Full Text] [Related]
17. Dengue virus neutralization and antibody-dependent enhancement activities of human monoclonal antibodies derived from dengue patients at acute phase of secondary infection.
Sasaki T; Setthapramote C; Kurosu T; Nishimura M; Asai A; Omokoko MD; Pipattanaboon C; Pitaksajjakul P; Limkittikul K; Subchareon A; Chaichana P; Okabayashi T; Hirai I; Leaungwutiwong P; Misaki R; Fujiyama K; Ono K; Okuno Y; Ramasoota P; Ikuta K
Antiviral Res; 2013 Jun; 98(3):423-31. PubMed ID: 23545366
[TBL] [Abstract][Full Text] [Related]
18. Identification of Dengue Virus Serotype 3 Specific Antigenic Sites Targeted by Neutralizing Human Antibodies.
Young E; Carnahan RH; Andrade DV; Kose N; Nargi RS; Fritch EJ; Munt JE; Doyle MP; White L; Baric TJ; Stoops M; DeSilva A; Tse LV; Martinez DR; Zhu D; Metz S; Wong MP; Espinosa DA; Montoya M; Biering SB; Sukulpolvi-Petty S; Kuan G; Balmaseda A; Diamond MS; Harris E; Crowe JE; Baric RS
Cell Host Microbe; 2020 May; 27(5):710-724.e7. PubMed ID: 32407709
[TBL] [Abstract][Full Text] [Related]
19. Dissecting the human serum antibody response to secondary dengue virus infections.
Patel B; Longo P; Miley MJ; Montoya M; Harris E; de Silva AM
PLoS Negl Trop Dis; 2017 May; 11(5):e0005554. PubMed ID: 28505154
[TBL] [Abstract][Full Text] [Related]
20. Functional Transplant of a Dengue Virus Serotype 3 (DENV3)-Specific Human Monoclonal Antibody Epitope into DENV1.
Messer WB; Yount BL; Royal SR; de Alwis R; Widman DG; Smith SA; Crowe JE; Pfaff JM; Kahle KM; Doranz BJ; Ibarra KD; Harris E; de Silva AM; Baric RS
J Virol; 2016 May; 90(10):5090-5097. PubMed ID: 26962223
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
